Dynamic Contrast-Enhanced MRI of Prostate Cancer

Prostate cancer is the most commonly diagnosed cancer in men in the United States of America with an estimated 198,000 new cases in 2001 (Greenlee et al. 2001). In the United Kingdom and the European Union, prostate cancer is the second most common cancer in men, with 20,000 new cases in the UK in 1997 (CRC 2001) and an estimated 134,000 new cases in the EU in 1996 (EUCAN). Substantial increases in incidence have been reported in recent years around the world, some of which can be attributed to frequent use of transurethral resection of the prostate (TURP) to treat symptoms of obstructive benign prostatic hyperplasia (BPH) and serum prostatespecifi c antigen (PSA) testing to screen for prostate cancer. While there is some debate on whether there is a real increase in incidence of prostate cancer, what is clear is that the population at risk (old men) continues to increase in size with lengthening of life expectancy. These factors make prostate cancer a large and growing healthcare problem for men. There are three major areas where imaging techniques may lead to improvements in the management of patients with suspected or proven prostate cancer (Thornbury et al. 2001). These are detection and localisation of early prostate cancer, identifi cation of men for whom treatment is likely to be curative and early detection of the site of recurrent disease: (1) Many men with a raised PSA level detected at screening do not have an underlying prostate cancer. Approximately 70%−80% of men do not have a prostate cancer diagnosed at the time of the raised PSA test but on long-term follow-up, 38% of men will develop prostate cancer if the presenting PSA lies between 4.1−10 ng/ml (Smith et al. 1996). (2) Once the diagnosis of cancer is made, it can be diffi cult to determine which patients will benefi t from treatment. The most appropriate treatment for localised prostate cancer remains controversial. Prostate cancer can be an indolent malignancy and yet contributes substantially to cancer mortality. Whilst a number of prognostic factors are recognised, new indices of biological activity are needed to help distinguish between clinically indolent and potentially life-threatening carcinomas (Bostwick et al. 2000). (3) Clinical evaluation of suspected recurrent cancer after radical local treatment can be challenging. An elevated PSA level may be the only evidence of treatment failure after local treatment. Determining the site of recurrence is important because men with an isolated local recurrence can benefi t from further treatments such as radiotherapy to a prostatectomy resection bed. The identifi cation of prostate cancer with a view to a targeted biopsy is the major current role for transrectal ultrasound (TRUS) (Clements 2001). Using TRUS, prostate cancer can be visualised as a hypoechoic lesion in the peripheral gland; however, lesions can appear hyperechoic or isoechoic. It should be noted that hypoechoic lesions in the peripheral gland are not necessarily cancers (41% are cancers overall, 52% if the PSA is raised and 71% if the PSA is raised with a palpable abnormality; Lee et al. 1989). With the increasing use of PSA screening there has been downward stage migration of diagnosed prostate cancer. As a result, it has become increasingly diffi cult CONTENTS

[1]  T. Kitamura,et al.  Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation , 1999, Cancer.

[2]  S. Torp-Pedersen,et al.  Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. , 1989, Radiology.

[3]  G P Liney,et al.  In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland , 1999, NMR in biomedicine.

[4]  S. F. Quinn,et al.  MR imaging of prostate cancer with an endorectal surface coil technique: correlation with whole-mount specimens. , 1994, Radiology.

[5]  H. Huisman,et al.  Accurate estimation of pharmacokinetic contrast‐enhanced dynamic MRI parameters of the prostate , 2001, Journal of magnetic resonance imaging : JMRI.

[6]  A R Padhani,et al.  MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.

[7]  M. Brawer,et al.  Comparison of microscopic vascularity in benign and malignant prostate tissue. , 1993, Human pathology.

[8]  J Kurhanewicz,et al.  Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. , 2001, Radiology.

[9]  H. Sanders,et al.  Ultrasound findings are not useful for defining stage Tic prostate cancer , 2005, World Journal of Urology.

[10]  A. Padhani Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.

[11]  A R Padhani,et al.  Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics , 1997, Journal of magnetic resonance imaging : JMRI.

[12]  T. D. de Reijke,et al.  Current Status of Minimally Invasive Treatment Options for Localized Prostate Carcinoma , 2000, European Urology.

[13]  W. Tilley,et al.  Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. , 1997, The Journal of urology.

[14]  M O Leach,et al.  Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter. , 2000, Magnetic resonance imaging.

[15]  J. Heiken,et al.  Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging. , 1993, Radiology.

[16]  M E Hammond,et al.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.

[17]  G J Parker,et al.  Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging. , 1999, Topics in magnetic resonance imaging : TMRI.

[18]  T. El-Diasty,et al.  Correlation between central zone perfusion defects on gadolinium-enhanced MRI and intraprostatic temperatures during transurethral microwave thermotherapy. , 2000, Journal of endourology.

[19]  E A Zerhouni,et al.  Nonpalpable prostate cancer: detection with MR imaging. , 1991, Radiology.

[20]  J. Moul Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy , 1999, European Urology.

[21]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[22]  C. Crone,et al.  THE PERMEABILITY OF CAPILLARIES IN VARIOUS ORGANS AS DETERMINED BY USE OF THE 'INDICATOR DIFFUSION' METHOD. , 1963, Acta physiologica Scandinavica.

[23]  C C Ling,et al.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[25]  L. Axel,et al.  Normal prostate and adjacent structures: MR imaging at 1.5 T. , 1987, Radiology.

[26]  F. Labrie,et al.  Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide. , 1992, Urology.

[27]  W. J. Lorenz,et al.  Pharmacokinetic Mapping of the Breast: A New Method for Dynamic MR Mammography , 1995, Magnetic resonance in medicine.

[28]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[29]  C C Ling,et al.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. , 2000, International journal of radiation oncology, biology, physics.

[30]  B. Rosen,et al.  Contrast agents in functional MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[31]  Henkjan J Huisman,et al.  Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. , 2003, Radiology.

[32]  M. Soloway,et al.  Histopathological effects of androgen deprivation in prostatic cancer. , 1996, Seminars in urologic oncology.

[33]  J. Allison,et al.  Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. , 1993, Magnetic resonance imaging.

[34]  D. Bostwick,et al.  Microvessel density in prostate cancer: prognostic and therapeutic utility. , 1998, Seminars in urologic oncology.

[35]  G Brix,et al.  Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. , 1998, Cancer research.

[36]  D P Dearnaley,et al.  Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. , 2000, Clinical radiology.

[37]  P H Bland,et al.  Carcinoma of the prostate: MR images obtained with body coils do not accurately reflect tumor volume. , 1991, AJR. American journal of roentgenology.

[38]  R. Babaian,et al.  Clinical efficacy of prostate cancer detection using power doppler imaging in American and Japanese men , 2002, Journal of clinical ultrasound : JCU.

[39]  A. Lorenz,et al.  Synergistic interaction of ultrasonic shock waves and hyperthermia in the dunning prostate tumor r3327‐at1 , 1999, International journal of cancer.

[40]  M. Soloway,et al.  Pathologic changes associated with androgen deprivation therapy for prostate cancer , 1991, Cancer.

[41]  V. Laudone,et al.  Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. , 1998, Urology.

[42]  P. Tofts Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[43]  C. Bartolozzi,et al.  Prediction of pathological tumor volume in clinically localized prostate cancer: value of endorectal coil magnetic resonance imaging , 1997, Magnetic Resonance Materials in Physics, Biology and Medicine.

[44]  C. Dinney,et al.  The role of angiogenesis in prostate and other urologic cancers: a review. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[45]  A R Padhani,et al.  Magnetic resonance imaging of prostate cancer: comparison of image quality using endorectal and pelvic phased array coils. , 1998, Clinical radiology.

[46]  D. Dearnaley,et al.  Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. , 1992, British journal of urology.

[47]  U. Patel,et al.  The diagnostic value of colour Doppler flow in the peripheral zone of the prostate, with histological correlation. , 1994, British journal of urology.

[48]  S. Leung,et al.  Proton magnetic resonance spectroscopy of late delayed radiation‐induced injury of the brain , 1999, Journal of magnetic resonance imaging : JMRI.

[49]  A. Bergh,et al.  Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. , 1999, The Journal of urology.

[50]  Herbert Y. Kressel,et al.  Prostatic carcinoma: staging with MR imaging at 1.5 T. , 1988 .

[51]  J. Rosenman Incorporating functional imaging information into radiation treatment. , 2001, Seminars in radiation oncology.

[52]  J. Kurhanewicz,et al.  Magnetic Resonance Imaging and Spectroscopic Imaging of Prostate Cancer , 2001, Cancer investigation.

[53]  K. Pienta,et al.  Tumor-associated angiogenesis in prostate cancer. , 1993, Anticancer research.

[54]  W E Reddick,et al.  Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. , 2000, Advanced drug delivery reviews.

[55]  J. Lewin,et al.  Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. , 1989, Radiology.

[56]  J Kurhanewicz,et al.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 1999, Radiology.

[57]  J. Overgaard,et al.  Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[58]  M. Rifkin,et al.  MR imaging characteristics of noncancerous lesions of the prostate , 1992, Journal of magnetic resonance imaging : JMRI.

[59]  H. Hricak,et al.  MR imaging of the seminal vesicles. , 1991, AJR. American journal of roentgenology.

[60]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[61]  J. McNeal,et al.  MR Depiction of Zonal Anatomy of the Prostate at 1.5 T , 1986, Journal of computer assisted tomography.

[62]  J Kurhanewicz,et al.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. , 2000, The Journal of urology.

[63]  A. Partin,et al.  Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate , 1997, Cancer.

[64]  I. Gribbestad,et al.  Comparative signal intensity measurements in dynamic gadolinium‐enhanced MR mammography , 1994, Journal of magnetic resonance imaging : JMRI.

[65]  J. Mohler,et al.  Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging. , 1991, The Journal of urology.

[66]  K. Yamada,et al.  Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. , 2003, The British journal of radiology.

[67]  W. Kaiser,et al.  MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. , 1989, Radiology.

[68]  A. Neugut,et al.  Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. , 1999, Urology.

[69]  T W Redpath,et al.  Measurement of spin-lattice relaxation times with FLASH for dynamic MRI of the breast. , 1996, The British journal of radiology.

[70]  P. Greenberg,et al.  Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. , 1998, Endocrinology.

[71]  S. Loening,et al.  Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer , 2000, The Prostate.

[72]  P. Kantoff,et al.  Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. , 1999, Urology.

[73]  P. Price,et al.  Functional CT Imaging of the Acute Hyperemic Response to Radiation Therapy of the Prostate Gland: Early Experience , 2001, Journal of computer assisted tomography.

[74]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[75]  G. Bartsch,et al.  Detection of prostate cancer with a microbubble ultrasound contrast agent , 2001, The Lancet.

[76]  L Axel,et al.  Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. , 1989, Radiology.

[77]  J. Debatin,et al.  Laser ablation-induced changes in the prostate: findings at endorectal MR imaging with histologic correlation. , 1997, Radiology.

[78]  Mark S. Cohen,et al.  Contrast agents and cerebral hemodynamics , 1991, Magnetic resonance in medicine.

[79]  R. Herfkens,et al.  Determining the volume of prostatic carcinoma: value of MR imaging with an external-array coil. , 1993, AJR. American journal of roentgenology.

[80]  M. Brawer,et al.  Serum basic fibroblast growth factor in men with and without prostate carcinoma , 1995, Cancer.

[81]  Gabriel P. Krestin,et al.  Contrast‐Enhanced Endorectal Coil MRI in Local Staging of Prostate Carcinoma , 1995, Journal of computer assisted tomography.

[82]  Andrew Jackson,et al.  Intensity-modulated radiotherapy. , 2002, Cancer journal.

[83]  G. Newstead,et al.  MR imaging of the breast. , 1995, Radiology.

[84]  J. Moul,et al.  CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. , 1998, The Journal of urology.

[85]  A. D'Amico,et al.  The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer , 1995 .

[86]  R E Lenkinski,et al.  Prostate cancer: local staging with endorectal surface coil MR imaging. , 1991, Radiology.

[87]  P. Troncoso,et al.  Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. , 1994, Urology.

[88]  Y. Collan,et al.  Prognostic factors in prostate cancer , 2006, Diagnostic pathology.

[89]  D. Bostwick,et al.  Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. , 1999, Urology.

[90]  H. Hricak,et al.  MR imaging of the prostate gland: normal anatomy. , 1987, AJR. American journal of roentgenology.

[91]  W. Murphy,et al.  Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone–‐releasing hormone effect). Distinction from poor tumor differentiation , 1994, Cancer.

[92]  J. Nelson,et al.  Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  Sherwood,et al.  Angiogenic peptides in prostatic disease , 1999, BJU international.

[94]  J R Thornbury,et al.  Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. , 1996, AJR. American journal of roentgenology.

[95]  J. Cho,et al.  Diffuse prostatic lesions: role of color Doppler and power Doppler ultrasonography. , 1998, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[96]  W. Catalona,et al.  Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.

[97]  Bostwick Dg Immunohistochemical changes in prostate cancer after androgen deprivation therapy. , 2000 .

[98]  Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. , 2002 .

[99]  A Horsman,et al.  Quantitative analysis of multi‐slice Gd‐DTPA enhanced dynamic MR images using an automated simplex minimization procedure , 1994, Magnetic resonance in medicine.

[100]  C P Langlotz,et al.  Prostate cancer: what is the future role for imaging? , 2001, AJR. American journal of roentgenology.

[101]  Janet E. Husband,et al.  The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma , 1995 .

[102]  M. Brawer,et al.  Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity , 1994, Cancer.

[103]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[104]  J. Richie,et al.  Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment. , 1998, The Journal of urology.

[105]  W J Manning,et al.  Studies of Gd‐DTPA relaxivity and proton exchange rates in tissue , 1994, Magnetic resonance in medicine.

[106]  S. Kitano,et al.  Diagnostic usefulness of endorectal magnetic resonance imaging with dynamic contrast‐enhancement in patients with localized prostate cancer: Mapping studies with biopsy specimens , 1999, International journal of urology : official journal of the Japanese Urological Association.

[107]  J R Thornbury,et al.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. , 1997, Radiology.

[108]  M. Schnall,et al.  Mucinous carcinomas involving the prostate: Atypical findings at MR imaging , 1992, Journal of magnetic resonance imaging : JMRI.

[109]  D P Dearnaley,et al.  Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[110]  C. Gatsonis,et al.  Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. , 1990, The New England journal of medicine.

[111]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[112]  D P Dearnaley,et al.  Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. , 1999, International journal of radiation oncology, biology, physics.

[113]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.

[114]  R. Bree The role of color Doppler and staging biopsies in prostate cancer detection. , 1997, Urology.

[115]  D P Dearnaley,et al.  Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. , 2001, Radiology.

[116]  E D Crawford,et al.  Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. , 1996, Urology.

[117]  Y. Yamashita,et al.  The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate. , 1998, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[118]  D M Shames,et al.  Quantification of the extraction fraction for gadopentetate across breast cancer capillaries , 1998, Magnetic resonance in medicine.

[119]  T Okada,et al.  Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. , 2001, Urology.

[120]  Mariann F. Brown,et al.  Microvascularity in benign prostatic hyperplasia , 1995, The Prostate.

[121]  S. Webb,et al.  Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. , 2002, The British journal of radiology.

[122]  R K Jain,et al.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[123]  M. Décorps,et al.  Methodology of brain perfusion imaging , 2001, Journal of magnetic resonance imaging : JMRI.

[124]  J. Rubin,et al.  Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. , 1995, Radiology.

[125]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[126]  P. Carroll,et al.  Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. , 1996, AJR. American journal of roentgenology.

[127]  G P Liney,et al.  Differentiation of prostatic carcinoma and benign prostatic hyperplasia: Correlation between dynamic Gd‐DTPA‐enhanced MR imaging and histopathology , 1999, Journal of magnetic resonance imaging : JMRI.

[128]  M. Murai,et al.  Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging , 1997, Cancer.